CASE STUDY
Transitioning from on-site to at-home assessments improved patient retention
and recruitment for a global neurology program.
Many neurologic disorders, such as ADHD, Alzheimer’s, depression, epilepsy, Parkinson’s disease, sclerosis, or schizophrenia, lack objective, easily measurable outcomes.
As complex neurological disease mechanisms are difficult to collect and interpret across heterogeneous patient populations, CNS clinical trials are often expensive and difficult to fund, especially for rare conditions.
Clinical ink eSource technology powers electronic data collection by consolidating Direct Data Capture (DDC), eCOA, ePRO, and eConsent.
It also integrates cognitive, mobility, and voice assessments using mobile, wearables, and sensor technology to work with a variety of CNS questionnaires and assessments, including:
Neurology often lacks biomarkers that are sensitive, specific, and noninvasive which can be a challenge for trials. Leading the way in digital biomarkers technology, Clinical ink offers the best-in-class analytics platform to capture, collect, and interpret real-time data powering the evaluation and development of new CNS treatments.
Our technology and tools are configurable for CNS study sites, so all stakeholders can easily and efficiently manage clinical trial data and gain:
Transitioning from on-site to at-home assessments improved patient retention
and recruitment for a global neurology program.
Sales and Solutions
Direct   1.336.464.0697
Support
Toll-Free 1.800.301.5033
Direct   1.336.464.0697
Insert HTML text here.
Transitioning from on-site to at-home assessments improved patient retention
and recruitment for a global neurology program.
Request more information, submit questions, set up a demonstration, and more.